The Patent Finder

Edimer Pharmaceuticals, Inc.

Also on record
Records under this name other than patents Edimer Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 7 of 7 · Back to Edimer Pharmaceuticals, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,925,239Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,426,819Treatment of X-Linked Hypohidrotic Ectodermal Dysplasia with a Fusion EDA1 Protein
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,175,085Treatment of X-linked Hypohidrotic Ectodermal Dysplasia with Ectodysplasin A Agonist
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,695,245Anti-ectodysplasin antibodies
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 10,300,013Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 8,741,297Preparation of isolated agonist anti-EDAR monoclonal antibodies
Formerly held
Lapsed on the fee record
Ended Jun 3, 2026 · USPTO record
Lapsed on the fee recordEnded Jun 3, 2026USPTO record
US 8,496,937Preparation of isolated agonist anti-EDAR monoclonal antibodies
Formerly held
Lapsed on the fee record
Ended Jul 30, 2025 · USPTO record
Lapsed on the fee recordEnded Jul 30, 2025USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited